Trial reportOpen forum infectious diseases2026
Immunobridging Analysis of Pemivibart for the Treatment of COVID-19: A Therapeutic Gap for the Immune-Compromised Population Remains.
Trial report in Open forum infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Multiple SARS-CoV-2 receptor-binding domain-directed monoclonal antibodies (mAbs) have demonstrated substantial efficacy for the treatment of COVID-19. However, rapid virus evolution challenges traditional development pathways, as nonsusceptible variants can outpace development and regulatory review. Fortunately, mAb antiviral activity across variants can be measured via clinical serum virus-neutralizing antibody titers that correlate to clinical outcomes from historical mAbs and serve as surrogate biomarkers for efficacy. Analytic immunobridging facilitates rapid assessment of novel mAb efficacy. Immunobridging supported the Emergency Use Authorization of pemivibart, a mAb targeted to the spike protein of SARS-CoV-2 for the prevention of COVID-19 in certain patients with immune compromise. We applied a similar framework to evaluate pemivibart for the treatment of acute COVID-19. Methods: Complementary methods included the following: (1) strict immunobridging of neutralizing antibody titers of pemivibart to its parent molecule adintrevimab, (2) benchmarking comparison of pemivibart to historical mAbs with demonstrated efficacy in COVID-19 treatment, and (3) dose-response analysis of pemivibart vs comparator mAbs based on a meta-analysis. Results: Pemivibart demonstrated strict immunobridging to adintrevimab from 4 to >14 days across the variants analyzed. Neutralizing titers of pemivibart were 4- to 12-fold higher than titers for sotrovimab and less than titers for other historical intravenously administered mAbs throughout a 14-day analysis period. Dose-response analysis predicted pemivibart to have equivalent efficacy to all comparators. Conclusions: Following a similar approach to prevention, immunobridging was demonstrated for pemivibart for the treatment of COVID-19, suggesting substantial antiviral activity. This development methodology provides a roadmap for accelerating novel COVID-19 treatment options amid a changing variant landscape.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.